Form 4 · Statement of Changes in Beneficial Ownership · Filed 2025-11-05
Geary Richard S Files Ionis Pharmaceuticals (IONS) Form 4 - November 05, 2025
Geary Richard S traded 69.3K IONS shares worth $4.7M in this Form 4 filing, reported to the SEC on 2025-11-05.
- Insider
- Geary Richard S
- Issuer
- Ionis Pharmaceuticals Inc. IONS · NASDAQ
- Filed
- Period
- 2025-11-05
- Accession
- 0000874015-25-000277
- Source
- Official filing on sec.gov ↗
Transactions (8)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Geary Richard S | 2025-11-06 | Sell | 18.3K | $75.42 | $1.4M | Direct |
| Geary Richard S | 2025-11-06 | Buy | 14.7K | $56.78 | $836.8K | Direct |
| Geary Richard S | 2025-11-06 | Sell | 14.7K | $76.10 | $1.1M | Direct |
| Geary Richard S | 2025-11-06 | Buy | 18.3K | $60.89 | $1.1M | Direct |
| Geary Richard S | 2025-11-05 | Buy | 800 | $56.78 | $45.4K | Direct |
| Geary Richard S | 2025-11-05 | Sell | 800 | $75.01 | $60.0K | Direct |
| Geary Richard S | 2025-11-05 | Buy | 801 | $60.89 | $48.8K | Direct |
| Geary Richard S | 2025-11-05 | Sell | 801 | $75.01 | $60.1K | Direct |
| Net change | 0 | −$576.5K | ||||
About Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc. is a biotechnology company focused on discovering and developing RNA-targeted therapeutics. The primary mission of Ionis is to harness its expertise in antisense oligonucleotide technology to address complex genetic disorders. Ionis is pioneering in the field of RNA-targeted drug discovery, aiming to treat a wide range of diseases, including neurological, cardiovascular, metabolic, and cancer-related conditions. Notably, the company has a robust pipeline of drugs in various stages of development and partnerships with leading pharmaceutical companies to expand the reach and impact of its therapeutic discoveries. As an innovative entity in the biotechnology sector, Ionis Pharmaceuticals plays a significant role in advancing medical treatments that target the underlying genetic causes of diseases, thereby offering new hope and potential solutions to patients worldwide. Its advancements contribute substantially to the growth and evolution of personalized medicine, emphasizing the importance of genetic research in modern healthcare.
Track IONS insider activity
Get alerted when Ionis Pharmaceuticals Inc. executives buy or sell their shares.